{
  "schema_version": "chamgap-public-criteria-1.0",
  "title": "Aged garlic extract 2.4-7.2 g/day × Reduction of ex vivo platelet aggregation",
  "language": "en",
  "translation_date": "2026-10-26",
  "criteria_version": "1.0",
  "criteria_date": "2026-10-05",
  "condition_origin": "Chamgap's own application conditions",
  "method_sources": [
    {
      "id": "M03",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03",
      "section": "§3.1, §3.2.1–3.2.3, MECIR C5/C7/C13",
      "official_principle": "Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.",
      "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed."
    },
    {
      "id": "M04",
      "version": "Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04",
      "section": "§4.5, §4.6.1–4.6.3, MECIR C42",
      "official_principle": "Distinguish studies from reports and link them; do not omit a study solely because results are unreported.",
      "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed."
    },
    {
      "id": "M08",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08",
      "section": "§8.1–8.2.3, Table 8.2.a",
      "official_principle": "Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.",
      "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed."
    },
    {
      "id": "M15",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15",
      "section": "§15.2.4, §15.3.1–15.3.3",
      "official_principle": "Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.",
      "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed."
    },
    {
      "id": "M19",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19",
      "section": "§19.1.2, §19.2.1–19.2.4",
      "official_principle": "Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.",
      "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed."
    }
  ],
  "status_dictionary": {
    "Met": "The stated retained information, reading, attribution or counting boundary was checked within limits. This does not certify efficacy, safety, full-text reading or reassessment.",
    "Partly verified": "Some retained information was checked, but material or conditions required by the criterion remain unverified.",
    "Unverified": "The criterion cannot be established in the retained record. This does not mean 0 studies, an effect of 0 or absence of harm.",
    "Not applicable": "This is limited to a specific application exception. It does not substitute for unread material.",
    "Review incomplete": "Remaining comparison work and its reason are stated separately. This is distinguished from unverified material."
  },
  "requirements": [
    {
      "item_id": "N01",
      "question_type": "Evidence condition",
      "question": "Is the ADP-induced ex vivo aggregation threshold linked as a separate question and distinguished from the original broad verdict?",
      "needed": "A record linking the original verdict claim, empty subclaims, derived question and parent verdict",
      "role": "Required",
      "role_reason": "This prevents biologically different agonist responses from being combined into one estimate or a new grade.",
      "application_exception": "Only this item evaluates the recorded boundary. Other items requiring actual dose, denominator and estimate material are assessed separately.",
      "criterion": "Retain the original wording, identify the ADP-induced ex vivo aggregation threshold as a separate target, and state that the derived ID is not an original array index.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "If the boundary changes, redefine the agonist, measure and comparison as a new question and preserve the previous version."
    },
    {
      "item_id": "N02",
      "question_type": "Evidence condition",
      "question": "Are S01's actual AGE formulation and SAC specification verified for the ADP comparison?",
      "needed": "Original product name, aging process, capsule content, batch SAC specification and actual administration data",
      "role": "Required",
      "role_reason": "Even the same extract name does not make raw garlic, powder, oil or isolated SAC interchangeable with AGE.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Link the actual AGE capsule product and ingredient specifications to the exposure used for ADP analysis.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "In controlled studies with matching products and batches, link the administered substance and ingredient specifications to the analysis cell."
    },
    {
      "item_id": "N03",
      "question_type": "Evidence condition",
      "question": "Is the 1995 garlic preparation the same formulation as the AGE exposure in this ADP question?",
      "needed": "Actual ingredients, processing, product and specifications of the 1995 preparation and a mapping to S01 AGE",
      "role": "Required",
      "role_reason": "This prevents another garlic preparation from being promoted to direct AGE replication or refutation.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Actual material must verify formulation and ingredient identity between the 1995 garlic preparation and S01 AGE.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "After checking formulation identity, compare whether the ADP measure matches; retain a separate preparation question if identity differs."
    },
    {
      "item_id": "N04",
      "question_type": "Evidence condition",
      "question": "Are the baseline status, eligibility and demographics of the actual ADP analysis population verified?",
      "needed": "S01 arm-specific age, sex, baseline platelet function, eligibility/exclusions and medication-use tables",
      "role": "Required",
      "role_reason": "A title-level description of mainly healthy adults cannot establish representation of a particular patient or co-medication group.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Link actual ADP specimen population characteristics and eligibility to S01's analysis population.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "In studies reporting baseline characteristics, compare selection and arm balance alongside the ADP results."
    },
    {
      "item_id": "N05",
      "question_type": "Evidence condition",
      "question": "Are the nominal dose list and the actual dose and intake for the ADP result linked?",
      "needed": "Arm-specific planned doses, actual intake, adherence data and dose mapping for the ADP result cell",
      "role": "Required",
      "role_reason": "This prevents automatic attribution of a shared dose list or another agonist's dose signal to this result.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Link each actual dose to its ADP result, comparator and time point; a nominal list alone does not establish a particular cell.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "After obtaining dose-specific comparison tables, analyze planned ADP dose comparisons separately from actual intake."
    },
    {
      "item_id": "N06",
      "question_type": "Evidence condition",
      "question": "Are exposure duration and the interval from the last dose to ADP blood collection and testing verified?",
      "needed": "S01 start/end dates, actual weeks of exposure, last-dose/blood-draw interval and testing time",
      "role": "Required",
      "role_reason": "This prevents short-term wording from becoming a specific number of weeks or a pharmacokinetic testing time.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Verify actual exposure duration and blood-draw/testing intervals by arm for the selected ADP analysis.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "In comparisons with a defined timeline, record pre/post exposure and last-dose intervals under the same conditions."
    },
    {
      "item_id": "N07",
      "question_type": "Evidence condition",
      "question": "Are the placebo's actual composition and common management verified for the ADP comparison?",
      "needed": "Placebo composition, dosing schedule, diet/management and arm differences",
      "role": "Required",
      "role_reason": "A placebo label alone cannot establish that AGE was the only difference.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Link placebo composition, schedule, common management and the actual comparison of interest to arm-specific data.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "In placebo comparisons with matching management, examine arm-specific management changes in relation to ADP results."
    },
    {
      "item_id": "N08",
      "question_type": "Evidence condition",
      "question": "Are the actual randomization, blinding and design procedures verified?",
      "needed": "Methods for sequence generation/concealment, parallel/crossover structure, blinding maintenance and baseline balance",
      "role": "Required",
      "role_reason": "This prevents a randomized double-blind summary from being read as proof of no allocation error.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Link S01's actual design, allocation/concealment and blinding methods to the ADP results.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "After comparing methods, assess allocation and specimen evaluation blinding according to the actual design."
    },
    {
      "item_id": "N09",
      "question_type": "Evidence condition",
      "question": "Can information on concomitant drugs, diet, adherence and exposure deviations affecting the ADP difference be verified?",
      "needed": "Arm-specific anticoagulants/antiplatelets, diet, rescue treatment, adherence/discontinuation and analysis handling",
      "role": "Required",
      "role_reason": "This keeps simultaneous exposures affecting platelet function separate from the selected intervention's contribution.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Link actual co-exposure, adherence, deviations and their handling to the ADP result population.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "In comparisons recording actual co-medication and deviations, review them according to the effect of interest and analysis handling."
    },
    {
      "item_id": "N10",
      "question_type": "Evidence condition",
      "question": "Are the exact measure, unit and direction of the ADP result verified?",
      "needed": "Original ADP result tables, threshold/maximum-aggregation definitions, units and positive cells",
      "role": "Required",
      "role_reason": "Agonists and measures represent different analyses; the aggregation label alone does not imply the same effect.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Link the selected ADP measure, unit and direction to the original table without substituting another measure.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "Fix the ADP measure and unit from the original result table before comparing between-arm results on the same measure."
    },
    {
      "item_id": "N11",
      "question_type": "Evidence condition",
      "question": "Are ADP concentration, specimen processing, equipment and repeated-specimen structure verified?",
      "needed": "Agonist concentration, PRP/specimen processing, equipment, measurement time and repeat/specimen identifiers",
      "role": "Required",
      "role_reason": "This prevents assuming that participant counts equal specimen counts or concentration-specific repeats.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Verify the concentration, specimen/equipment and repeat structure of the selected ADP response.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "Specify matching concentration, specimen processing and assay methods, and design comparisons accounting for within-person repeats."
    },
    {
      "item_id": "N12",
      "question_type": "Evidence condition",
      "question": "Which between-arm contrast and analysis population does the selected ADP value estimate?",
      "needed": "Baseline change/end values, between/within-arm comparisons, ITT/PP, models and dose/concentration-specific repeat handling",
      "role": "Required",
      "role_reason": "This prevents converting a directional summary into a formal placebo contrast or adjusted effect.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Verify the actual analysis, denominator, model and measure definition for the between-arm contrast of interest.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "Compare the original analysis or an appropriate comparison model specifying the between-arm contrast; retain within-arm change separately."
    },
    {
      "item_id": "N13",
      "question_type": "Evidence condition",
      "question": "Can the original 34 people be distinguished from dose-specific ADP allocation, measurement and analysis denominators?",
      "needed": "Flow of total recruitment/allocation, dose/control-specific measured/analyzed people and specimen counts",
      "role": "Required",
      "role_reason": "This prevents dividing a shared trial total into dose/endpoint analysis n or adding it across three tables.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Use actual material to distinguish the original 34-person sample description from dose/control and ADP analysis denominators.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "Compare person/specimen identifier flow and state the analysis unit and arm-specific denominators."
    },
    {
      "item_id": "N14",
      "question_type": "Evidence condition",
      "question": "Are missingness, losses, failed measurements and their handling verified for the ADP analysis?",
      "needed": "Dose-arm loss reasons, specimen/result missingness, analysis exclusions, imputation/sensitivity analyses",
      "role": "Required",
      "role_reason": "The 34-person count and directional summary cannot establish that everyone was measured and analyzed.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Link selected ADP measurement/analysis losses and their handling to the actual flow.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "Review how missingness affects the contrast of interest using original data recording the types of omission."
    },
    {
      "item_id": "N15",
      "question_type": "Evidence condition",
      "question": "Are the formal ADP effect estimate, variance, P value and confidence interval verified?",
      "needed": "Dose/concentration/time-specific arm values, SD/SE, between-arm estimate, P/CI and denominators",
      "role": "Required",
      "role_reason": "This prevents partial reduction or a weak signal from establishing magnitude, precision or significance.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Link the formal ADP estimate and variance/interval to the corresponding analysis cell.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "Obtain original estimates and intervals on the same ADP measure to compare magnitude and uncertainty."
    },
    {
      "item_id": "N16",
      "question_type": "Evidence condition",
      "question": "Do the registered/protocol/SAP prespecified ADP endpoint and report agree?",
      "needed": "S01 actual registration identifier, protocol, SAP, dates/versions and analysis hierarchy",
      "role": "Required",
      "role_reason": "Planning material is needed to examine possible selection of favorable findings among multiple agonists.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Compare prespecified ADP endpoints, doses, concentrations, time points and analyses with results.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "Compare dated plans and result tables to distinguish prespecified from post hoc analyses of the selected response."
    },
    {
      "item_id": "N17",
      "question_type": "Evidence condition",
      "question": "Are the testing scope and adjustment for multiple doses, agonists, concentrations/time points verified?",
      "needed": "Testing family, prespecified primary/secondary endpoints, all analysis tables and multiplicity handling",
      "role": "Required",
      "role_reason": "This prevents multiple responses from one shared trial from becoming independent confirmations.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Verify the selected ADP result's hierarchy within all testing and its actual handling.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "Examine multiple contrasts and selective reporting in plan-based analyses disclosing all results."
    },
    {
      "item_id": "N18",
      "question_type": "Evidence condition",
      "question": "Can the reported ADP direction be verified down to the actual measure and dose cell?",
      "needed": "All favorable/no-difference/unfavorable cells of the selected response and exact analysis locations",
      "role": "Required",
      "role_reason": "This prevents a positive direction from becoming a claim of effects at every dose and concentration.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Retain the original direction while verifying its ADP measure, dose, concentration and time-point cell.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "Compare all prespecified ADP dose/concentration cells, including cells without favorable results."
    },
    {
      "item_id": "N19",
      "question_type": "Evidence condition",
      "question": "Is S02's null ADP result verified as the same AGE and measure comparison?",
      "needed": "S02 formulation, population, concentration, measure, formal estimate, denominator and P/CI",
      "role": "Required",
      "role_reason": "This retains opposing results without erasing unverified identity.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Verify whether S02's ADP comparison uses the selected AGE formulation and matching measure/concentration; compare the scope of its original no-difference estimate.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "Compare positive/opposing original tables by formulation and measure; do not interpret nonsignificance as an effect of 0 or equivalence."
    },
    {
      "item_id": "N20",
      "question_type": "Evidence condition",
      "question": "Are the AGE/ADP original trials and results in the 2022 review verified?",
      "needed": "Review included-trial table and mapping of formulation, agonist, dose, population and endpoint to original results",
      "role": "Required",
      "role_reason": "This prevents reusing 12 RCTs and 595 people as the direct trials/denominator for this specific AGE response.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Distinguish the review's directly relevant AGE/ADP trials using the actual included-trial table.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "Compare included trials with original reports, separate formulation/response-specific results and identify participant overlap."
    },
    {
      "item_id": "N21",
      "question_type": "Evidence condition",
      "question": "Are independent replication and unique participant counts for the same ADP/AGE question verified?",
      "needed": "Report/original-trial/cohort, included-trial overlap and response-specific analysis mapping",
      "role": "Required",
      "role_reason": "This prevents counting the shared 34-person trial, a related-preparation trial and a review as independent replications or unique-participant totals.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Verify matching formulation, response and comparison relationships for unique trials/participants using actual linking material.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "After checking actual study families and included-trial overlap, examine replication of the same ADP question."
    },
    {
      "item_id": "N22",
      "question_type": "Evidence condition",
      "question": "Are important-difference and interpretation criteria justified for this ADP measure?",
      "needed": "Measure-specific prespecified important difference, assay reproducibility/variation, rationale and original intervals",
      "role": "Required",
      "role_reason": "A weak/partial direction without numbers cannot establish an important or sufficient effect.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Verify the important-difference rationale for the selected measure together with the reported interval.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "Specify reproducibility and a justified important difference for the measure, then compare them with formal estimates and intervals."
    },
    {
      "item_id": "N23",
      "question_type": "Evidence condition",
      "question": "Is the boundary between the selected ex vivo ADP response and clinical thrombosis/bleeding events distinguished?",
      "needed": "A record linking the experimental endpoint to the scope of clinical-event/alternative-treatment claims",
      "role": "Supplementary; required for clinical-event extensions",
      "role_reason": "This prevents a specimen response from becoming thrombosis prevention, thrombolysis, aspirin replacement or bleeding safety.",
      "application_exception": "Clinical-event trials are not universally required to verify the narrow experimental response. Clinical extension claims need separate direct material.",
      "criterion": "Keep the selected experimental endpoint separate from unmeasured clinical thrombosis/bleeding questions.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "If clinical events are the question, examine them in separate comparisons with suitable populations, follow-up and event collection."
    },
    {
      "item_id": "N24",
      "question_type": "Evidence condition",
      "question": "Is the current scope of PAF, arachidonic acid and other responses distinguished from the ADP result?",
      "needed": "Current agonist-specific report lists, unverified PAF formulation identity and the AA result gap",
      "role": "Required",
      "role_reason": "This prevents transferring adjacent agonist names or another preparation's results to the selected ADP result.",
      "application_exception": "This criterion checks only the current reporting scope. Successful distinction here does not satisfy actual PAF/AA material requirements.",
      "criterion": "Keep S02 PAF as context with unverified identity and AA as a result gap named only in the crux; do not combine them with the selected response.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "When new original material for each response appears, define formulation, measure, concentration and comparator separately and examine it in a separate table version."
    },
    {
      "item_id": "N25",
      "question_type": "Evidence condition",
      "question": "Is there direct material on optimal dose, long-term persistence and ADP response after discontinuation?",
      "needed": "Prespecified between-dose comparisons, exposure/withdrawal follow-up, long-term ADP results and interactions",
      "role": "Supplementary; required for dose/persistence extensions",
      "role_reason": "This prevents some short-term multi-dose directions from becoming an optimal-dose or persistent-effect claim.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Verify direct comparison and follow-up material matching the extension question.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "If persistence or dose optimization is the objective, design separate prespecified dose comparisons and withdrawal/long-term follow-up."
    },
    {
      "item_id": "N26",
      "question_type": "Evidence condition",
      "question": "Are actual bleeding, adverse-event and discontinuation collection data verified for the same AGE exposure?",
      "needed": "Event definitions, active/spontaneous collection, timing, exposure/denominators, severity and discontinuation tables",
      "role": "Supplementary; required for harm interpretation",
      "role_reason": "This prevents platelet responses or warning sentences from becoming actual adverse-event collection results or safety certification.",
      "application_exception": "Separate this experimental aggregation comparison from actual harms. Unverified event material does not mean 0 adverse events, safety or absence of experimental results.",
      "criterion": "Link actual harm events, collection methods, exposure duration, denominators and discontinuation outcomes to the same population/exposure.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "For harm questions, examine separate material with event definitions, collection systems and appropriate follow-up."
    },
    {
      "item_id": "N27",
      "question_type": "Evidence condition",
      "question": "Is direct harm information verified for anticoagulant/antiplatelet co-use, bleeding disorders and surgical populations?",
      "needed": "Exposure, baseline risk, duration, harm events and comparison material in vulnerable/co-medication groups",
      "role": "Supplementary; required for vulnerable-group safety extensions",
      "role_reason": "This prevents extrapolating responses mainly from healthy adults to safety in high-risk populations.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Verify direct exposure/event material and interaction information for each relevant group.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "For co-medication/vulnerable-group questions, use suitable separate comparison/follow-up designs recording baseline risk and actual exposure."
    },
    {
      "item_id": "N28",
      "question_type": "Evidence condition",
      "question": "Are actual funding, product support and employment/COI disclosures verified for the ADP material?",
      "needed": "Original S01/S02 funding, product support, author employment/patents/COI and S03 included-trial material",
      "role": "Supplementary; required for independence claims",
      "role_reason": "This prevents an original independent-summary label or academic-research wording from establishing independent funding or no product provision.",
      "application_exception": "This criterion requires actual material verification for the ADP-induced ex vivo aggregation threshold. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.",
      "criterion": "Check actual disclosures and product-support scope separately for each report/original trial.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "Compare original disclosures and interpret results separately from study families and product support."
    },
    {
      "item_id": "N29",
      "question_type": "Evidence condition",
      "question": "Are study-family and review-recitation relationships for the three reports and shared ADP results stated?",
      "needed": "Verified/unverified relationships among 3 reports, PMID/DOI, shared trials and review inclusion",
      "role": "Required",
      "role_reason": "Bibliographic record counts must be distinguished from independent study counts.",
      "application_exception": "This evaluates only the distinction of recorded relationships. Success does not establish direct replication or unique study counts.",
      "criterion": "Record the shared 34-person S01 trial, related S02 preparation, S03 review and uncertain inclusion relationships separately.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "Compare original trial identifiers with included-trial tables and update links when new overlap relationships are found."
    },
    {
      "item_id": "N30",
      "question_type": "Evidence condition",
      "question": "Are the original broad C46, all axes and the English-placeholder correction event preserved?",
      "needed": "The complete original record, both languages, axes, empty arrays/strings and original correction location/date",
      "role": "Required",
      "role_reason": "This prevents using historical scores to determine condition status or promoting generic verification English into actual analysis values.",
      "application_exception": "This is a preservation criterion and does not satisfy unverified clinical-material requirements in other items.",
      "criterion": "Preserve original grade/score/axes, both languages and correction wording in their original types; create no separate ADP grade.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "For future corrections, separate the before-text, event, new version and reason, then compare related observations/conditions."
    },
    {
      "item_id": "N31",
      "question_type": "Evidence condition",
      "question": "Are the original review date, correction date and current review scope distinguished?",
      "needed": "Original verdict-review date, correction event, currently read inputs and records of absent cut-off/access fields",
      "role": "Required",
      "role_reason": "This prevents backdating actual individual access or a latest search cut-off to the historical review date.",
      "application_exception": "This criterion labels the sheet’s scope. It does not establish a successful new search or resolution of clinical gaps.",
      "criterion": "Distinguish local retained-record conversion from historical review/correction; do not infer absent cut-off or access dates.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "If new material is permitted, add search/access/review dates and actual locations as separate events."
    },
    {
      "item_id": "N32",
      "question_type": "Evidence condition",
      "question": "Are current local-summary reading and unread external gateways/full texts distinguished by material?",
      "needed": "Exact input locations/identity and actual actions for PubMed, DOI and full-text materials",
      "role": "Required",
      "role_reason": "This prevents an external link or historical verification wording from becoming current full-text reading.",
      "application_exception": "External access not attempted is not access failure. Satisfying this recording criterion is separate from satisfying clinical-material requirements.",
      "criterion": "Link local retained-record reading to actual locations; keep external material as not attempted/unread with false flags.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "For permitted new reading, separately record material type, version, success/failure, sections read, original location and identity."
    },
    {
      "item_id": "N33",
      "question_type": "Evidence condition",
      "question": "Is the remaining scope of external original-table, method and registration comparison stated?",
      "needed": "ADP original result tables, methods/appendices, actual registration/SAP identity and currently uncompared locations",
      "role": "Required",
      "role_reason": "This prevents retained-record self-review from being read as original-paper/official-method execution or independent clinical certification.",
      "application_exception": "This recording criterion states current review scope. Unperformed review is not promoted to a verified clinical comparison or safety.",
      "criterion": "Distinguish retained locations actually read from unread external original tables/methods/registration.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are Chamgap in-house application conditions for the aged-garlic-extract ADP-induced ex vivo aggregation-threshold question, developed with knowledge of the retained content. They do not establish blinding, trial preregistration, official-tool certification or independent clinical validation.",
      "proposed_research": "If new external comparison is authorized, distinguish material acquisition from analysis methods and update each item according to actual results."
    }
  ]
}